FDA grants Vitrase 5 years' exclusivity

December 1, 2004

The FDA has extended ISTA Pharmaceuticals' market exclusivity for hyaluronidase for injection (Vitrase) to 5 years from 3 years. The exclusivity will end May 5, 2009.